• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。

Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.

机构信息

Barcelona Institute for Global Health (ISGlobal) Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.

Hematology Department, Hospital Clínic, Barcelona, Spain.

出版信息

Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.

DOI:10.1016/j.ijid.2020.12.050
PMID:33359065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7832789/
Abstract

Microbiological response of SARS-CoV-2 to remdesivir in immunocompromised patients has not been evaluated. We present the case of a severely immunocompromised patient with persistent replication of SARS-CoV-2, who required different courses of remdesivir. Short courses of remdesivir might be insufficient in immunocompromised patients due to prolonged viral clearance.

摘要

尚未评估瑞德西韦在免疫功能低下患者中对 SARS-CoV-2 的微生物学反应。我们报告了一例严重免疫功能低下的患者，其 SARS-CoV-2 持续复制，需要不同疗程的瑞德西韦。由于病毒清除时间延长，免疫功能低下患者可能需要较短疗程的瑞德西韦治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7832789/cd4c69a30e9a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7832789/cd4c69a30e9a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65c5/7832789/cd4c69a30e9a/gr1_lrg.jpg

相似文献

1
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.严重免疫功能低下患者接受多疗程瑞德西韦治疗后，SARS-CoV-2 持续复制。
Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.
2
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.替沙格韦单抗/西加韦单抗与瑞德西韦联合治疗对免疫功能低下患者持续性SARS-CoV-2感染的反应欠佳。
J Antimicrob Chemother. 2024 May 2;79(5):1196-1200. doi: 10.1093/jac/dkae082.
3
Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.关于：替沙格韦单抗/西加韦单抗与瑞德西韦联合治疗免疫功能低下患者持续性SARS-CoV-2感染疗效欠佳的评论
J Antimicrob Chemother. 2024 Sep 3;79(9):2400-2402. doi: 10.1093/jac/dkae234.
4
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.皮下注射瑞德西韦可预防感染 SARS-CoV-2 的恒河猴发生间质性肺炎。
Antiviral Res. 2022 Feb;198:105246. doi: 10.1016/j.antiviral.2022.105246. Epub 2022 Jan 13.
5
Update Alert 2: Remdesivir for Adults With COVID-19.最新警报2：用于成人新冠肺炎患者的瑞德西韦。
Ann Intern Med. 2021 Dec;174(12):W114-W115. doi: 10.7326/L21-0600. Epub 2021 Oct 5.
6
The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.叶酸拮抗剂甲氨蝶呤可抑制冠状病毒 SARS-CoV-2 的复制，并增强瑞德西韦在细胞培养模型中的抗病毒疗效。
Virus Res. 2021 Sep;302:198469. doi: 10.1016/j.virusres.2021.198469. Epub 2021 Jun 6.
7
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.联合使用甲基强的松龙和瑞德西韦对 SARS-CoV-2 感染仓鼠模型的有益作用。
Emerg Microbes Infect. 2021 Dec;10(1):291-304. doi: 10.1080/22221751.2021.1885998.
8
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients.瑞德西韦治疗和未治疗的 SARS-CoV-2 感染儿科患者中病毒变异株的演变。
J Med Virol. 2022 Jan;94(1):161-172. doi: 10.1002/jmv.27285. Epub 2021 Sep 4.
9
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.新视角下的抗菌药物：瑞德西韦治疗 COVID-19。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01814-20.
10
Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.瑞德西韦：从埃博拉病毒病到 COVID-19 的希望之光。
Rev Med Virol. 2020 Nov;30(6):1-13. doi: 10.1002/rmv.2133. Epub 2020 Jul 30.

引用本文的文献

1
Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report.肾功能受损的肾移植患者中VV116的严重代谢蓄积：病例系列报告
Front Immunol. 2025 Jan 17;15:1501813. doi: 10.3389/fimmu.2024.1501813. eCollection 2024.
2
Antiviral combination treatment of SARS-CoV-2 after repeated treatment failures of remdesivir monotherapy: A case report.瑞德西韦单药反复治疗失败后对严重急性呼吸综合征冠状病毒2进行抗病毒联合治疗：一例报告
IDCases. 2024 Nov 13;38:e02118. doi: 10.1016/j.idcr.2024.e02118. eCollection 2024.
3
Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.

本文引用的文献

1
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
2
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.免疫功能低下患者持续性 COVID-19 经瑞德西韦两疗程治疗暂时起效
J Infect Dis. 2020 Sep 1;222(7):1103-1107. doi: 10.1093/infdis/jiaa446.
3
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
COVID-19 后难治性高级别 B 细胞淋巴瘤的嵌合抗原受体 T 细胞治疗。
Int J Hematol. 2024 Apr;119(4):459-464. doi: 10.1007/s12185-024-03711-5. Epub 2024 Feb 13.
4
Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient.奥密克戎变异株超感染后免疫功能低下的儿科患者中 SARS-CoV-2 Delta 的再现。
Virol J. 2023 Oct 27;20(1):246. doi: 10.1186/s12985-023-02186-w.
5
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review.新冠疫情急性期过渡期间的关键考量因素：一项叙述性综述
Vaccines (Basel). 2023 Sep 19;11(9):1502. doi: 10.3390/vaccines11091502.
6
Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma.在一例接受恶性淋巴瘤B细胞清除免疫治疗后出现长时间新冠病毒感染的病例中，使用瑞德西韦和恩西他韦进行成功的双重抗病毒治疗。
IDCases. 2023 Aug 30;34:e01890. doi: 10.1016/j.idcr.2023.e01890. eCollection 2023.
7
Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.造血干细胞移植受者高危 SARS-CoV-2 感染的有效病毒特异性 T 细胞治疗：初步病例研究和文献复习。
Geroscience. 2024 Feb;46(1):1083-1106. doi: 10.1007/s11357-023-00858-7. Epub 2023 Jul 6.
8
Remdesivir Use in the Real-World Setting: An Overview of Available Evidence.瑞德西韦在真实世界环境中的应用：现有证据概述。
Viruses. 2023 May 14;15(5):1167. doi: 10.3390/v15051167.
9
Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir.一名弥漫性大 B 细胞淋巴瘤患者的 SARS-CoV-2 奥密克戎变异株持续感染，经三剂瑞德西韦治疗后成功清除。
J Infect Chemother. 2023 Aug;29(8):820-824. doi: 10.1016/j.jiac.2023.05.003. Epub 2023 May 12.
10
Coronavirus Disease-2019 in the Immunocompromised Host.新型冠状病毒病在免疫功能低下宿主中的研究进展
Clin Chest Med. 2023 Jun;44(2):395-406. doi: 10.1016/j.ccm.2022.11.012. Epub 2022 Nov 22.
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
4
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
5
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
6
COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster.COVID-19 于长期使用糖皮质激素患者：家族聚集性病例研究。
Clin Immunol. 2020 May;214:108413. doi: 10.1016/j.clim.2020.108413. Epub 2020 Apr 8.
7
Clinical and virological data of the first cases of COVID-19 in Europe: a case series.欧洲首批 COVID-19 病例的临床和病毒学数据：一项病例系列研究。
Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.